BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32193356)

  • 41. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
    Troutman MD; Thakker DR
    Pharm Res; 2003 Aug; 20(8):1210-24. PubMed ID: 12948019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
    Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
    Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
    Choi MK; Song IS
    J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
    Hoque MT; Kis O; De Rosa MF; Bendayan R
    Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Stereochemical Configuration on the Transport and Metabolism of Catechins from Green Tea across Caco-2 Monolayers.
    Ai Z; Liu S; Qu F; Zhang H; Chen Y; Ni D
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30917581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine.
    Xie QS; Zhang JX; Liu M; Liu PH; Wang ZJ; Zhu L; Jiang L; Jin MM; Liu XN; Liu L; Liu XD
    Acta Pharmacol Sin; 2021 Mar; 42(3):470-481. PubMed ID: 32555444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats.
    Suzuki K; Taniyama K; Aoyama T; Watanabe Y
    Xenobiotica; 2020 Sep; 50(9):1121-1127. PubMed ID: 31868552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
    Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
    Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
    Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
    J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
    Troutman MD; Thakker DR
    Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers.
    Liang E; Proudfoot J; Yazdanian M
    Pharm Res; 2000 Oct; 17(10):1168-74. PubMed ID: 11145220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IPEC-J2 MDR1, a Novel High-Resistance Cell Line with Functional Expression of Human P-glycoprotein (ABCB1) for Drug Screening Studies.
    Saaby L; Helms HC; Brodin B
    Mol Pharm; 2016 Feb; 13(2):640-52. PubMed ID: 26651362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
    Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
    Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
    Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversible inhibition of efflux transporters by hydrogel microdevices.
    Levy ES; Samy KE; Lamson NG; Whitehead KA; Kroetz DL; Desai TA
    Eur J Pharm Biopharm; 2019 Dec; 145():76-84. PubMed ID: 31639417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
    Liao M; Chuang BC; Zhu Q; Li Y; Guan E; Yu S; Yang J; Prakash S; Xia CQ
    Xenobiotica; 2018 May; 48(5):467-477. PubMed ID: 28485193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.